TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35090638

Group type: EXPERIMENTAL
Intervention: 5 7mu;g CoV2 preS dTM with AS03
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: 10 7mu;g CoV2 preS dTM with AS03
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: 15 7mu;g CoV2 preS dTM with AS03
Number of subjects: 722
Study: 32976844

Group type: EXPERIMENTAL
Intervention: Microprocessor swing and stance controlled knee‐ankle‐foot orthosis (MPO)
Number of subjects: 18
Study: 35279201

Group type: EXPERIMENTAL
Intervention: Stromal vascular fraction (SVF)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Hyaluronic acid (HA)
Number of subjects: 126
Study: 32873466

Group type: EXPERIMENTAL
Intervention: 3‐0 knotless barbed suture (polydioxanone)
Number of subjects: 25

Group type: COMPARATOR
Intervention: 4‐0 polyglactin 910 (vicryl)
Number of subjects: 25
Study: 34181362

Group type: EXPERIMENTAL
Intervention: Suvorexant 30 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Zolpidem 5 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 35101085

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg daily for 6 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 33040590

Group type: EXPERIMENTAL
Intervention: Smartphone application for rehabilitation
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard rehabilitation (Control)
Number of subjects: 101
Study: 34047794

Group type: EXPERIMENTAL
Intervention: Restricted mean duration of response (DOR)
Number of subjects: 1376

Group type: EXPERIMENTAL
Intervention: Restricted mean DOR
Number of subjects: 1376

Group type: EXPERIMENTAL
Intervention: Progression-free survival (PFS)
Number of subjects: 1376

Group type: EXPERIMENTAL
Intervention: Objective response rate (ORR)
Number of subjects: 1376
Study: 616065144

Group type: EXPERIMENTAL
Intervention: Single nurse-led home health care visit after discharge
Number of subjects: 1500
Study: 33991330

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 90
Study: 34078324

Group type: EXPERIMENTAL
Intervention: Supportive-Expressive Treatment (SET)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Emotion-Focused Treatment (EFT)
Number of subjects: 124

Group type: COMPARATOR
Intervention: SET and EFT
Number of subjects: 124
Study: 32353218

Group type: EXPERIMENTAL
Intervention: Combined exercise training (resistance and aerobic) 3 days/week for 60 minutes
Number of subjects: 53

Group type: COMPARATOR
Intervention: Routine clinical orientations
Number of subjects: 53
Study: 35238397

Group type: EXPERIMENTAL
Intervention: CJR model
Number of subjects: 17447

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 17447
Study: 32751522

Group type: EXPERIMENTAL
Intervention: Magnesium (500 mg/day)
Number of subjects: 52
Study: 33656950

Group type: EXPERIMENTAL
Intervention: Arthroscopic surgery with postoperative physical therapy (SPT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Physical therapy alone (PTA)
Number of subjects: 90
Study: 35029879

Group type: EXPERIMENTAL
Intervention: MBSR therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 0
Study: 32501761

Group type: EXPERIMENTAL
Intervention: AndoFlex TLC Calamine
Number of subjects: 39

Group type: COMPARATOR
Intervention: Coban2
Number of subjects: 39
Study: 33829499

Group type: EXPERIMENTAL
Intervention: Online-delivered intervention (ODI)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Staff-delivered intervention (SDI)
Number of subjects: 334
Study: 33346782

Group type: EXPERIMENTAL
Intervention: Ticagrelor added to aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 0
Study: 36069630

Group type: EXPERIMENTAL
Intervention: Enriched pain management (EPM) pathway integrating physical therapy and mindfulness
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care pain management (UC)
Number of subjects: 0
Study: 32703548

Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy (haemoglobin, 90–110 g L−1)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Restrictive transfusion strategy (haemoglobin, 70–90 g L−1)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Restrictive transfusion strategy
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy
Number of subjects: 200
Study: 35981755

Group type: EXPERIMENTAL
Intervention: Hybrid closed-loop insulin delivery
Number of subjects: 0
Study: 32985946

Group type: EXPERIMENTAL
Intervention: Caffeine (3-mg/kg bodyweight)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (3-mg/kg bodyweight lactose)
Number of subjects: 0
Study: 32853821

Group type: EXPERIMENTAL
Intervention: Asthma Symptom Index (ASI)
Number of subjects: 1218

Group type: EXPERIMENTAL
Intervention: Asthma Symptom Utility Index (ASUI)
Number of subjects: 1218

Group type: COMPARATOR
Intervention: Asthma Control Questionnaire (ACQ-5)
Number of subjects: 1218

Group type: COMPARATOR
Intervention: St George's Respiratory Questionnaire (SGRQ)
Number of subjects: 1218
Study: 32719000

Group type: EXPERIMENTAL
Intervention: Cytomegalovirus (CMV)-specific dendritic cell (DC) vaccines
Number of subjects: 200
Study: 35779909

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 33604869

Group type: EXPERIMENTAL
Intervention: Bariatric Surgery (BS)
Number of subjects: 1322

Group type: COMPARATOR
Intervention: Non-Surgical (NS)
Number of subjects: 1322

Group type: COMPARATOR
Intervention: General Population (GP)
Number of subjects: 1322
Study: 36389329

Group type: EXPERIMENTAL
Intervention: VivaSight double-lumen tube
Number of subjects: 71

Group type: COMPARATOR
Intervention: Standard double-lumen tube (DLT)
Number of subjects: 71
Study: 32586395

Group type: EXPERIMENTAL
Intervention: gammaCore®-Sapphire device plus standard of care
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard of care alone (SoC)
Number of subjects: 90
Study: 33922323

Group type: EXPERIMENTAL
Intervention: Envelope flap (EF)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Szmyd flap (SF)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both EF and SF
Number of subjects: 60
Study: 32951360

Group type: EXPERIMENTAL
Intervention: Attended systolic blood pressure measurement
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Unattended systolic blood pressure measurement
Number of subjects: 102

Group type: COMPARATOR
Intervention: Routine clinic systolic blood pressure measurement
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Comparison of attended vs unattended SBP
Number of subjects: 102

Group type: COMPARATOR
Intervention: Comparison of routine clinic SBP vs attended SBP
Number of subjects: 102

Group type: COMPARATOR
Intervention: Comparison of routine clinic SBP vs unattended SBP
Number of subjects: 102
Study: 35331810

Group type: EXPERIMENTAL
Intervention: Post-PCI QFR assessment in patients with diabetes mellitus (DM)
Number of subjects: 2227

Group type: EXPERIMENTAL
Intervention: Post-PCI QFR assessment in patients without diabetes (non-DM)
Number of subjects: 2227

Group type: EXPERIMENTAL
Intervention: Suboptimal post-PCI QFR results (≤0.92) in patients with diabetes mellitus (DM)
Number of subjects: 2227

Group type: EXPERIMENTAL
Intervention: Suboptimal post-PCI QFR results (≤0.92) in patients without diabetes (non-DM)
Number of subjects: 2227
Study: 33567336

Group type: EXPERIMENTAL
Intervention: Dry Needling (DN)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sham Dry Needling
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 32469183

Group type: EXPERIMENTAL
Intervention: Relugolix (120 mg orally once daily)
Number of subjects: 930

Group type: COMPARATOR
Intervention: Leuprolide (injections every 3 months)
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: Relugolix
Number of subjects: 930

Group type: COMPARATOR
Intervention: Leuprolide
Number of subjects: 930
Study: 34908015

Group type: EXPERIMENTAL
Intervention: Low-iron formula with added bovine lactoferrin (1.0 g/L)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Low-iron formula with no added lactoferrin
Number of subjects: 180

Group type: COMPARATOR
Intervention: Standard formula at 8 mg/L iron and no added lactoferrin (control formula)
Number of subjects: 180
Study: 33198761

Group type: EXPERIMENTAL
Intervention: PB-ARS
Number of subjects: 34

Group type: COMPARATOR
Intervention: Traditional presentation (Control Group)
Number of subjects: 34
Study: 34182833

Group type: EXPERIMENTAL
Intervention: Specific injury prevention neuromuscular training programme (SIPP)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Active general control (GIPP)
Number of subjects: 14
Study: 34080821

Group type: EXPERIMENTAL
Intervention: Doppler-guided hemorrhoid artery ligation with suture mucopexy (DGHAL-SM)
Number of subjects: 80

Group type: COMPARATOR
Intervention: LigaSure™-assisted pile excision (LAP)
Number of subjects: 80
Study: 36270673

Group type: EXPERIMENTAL
Intervention: Physical activity promotion program (intervention group)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 43
Study: 34446483

Group type: EXPERIMENTAL
Intervention: Community-based intervention with integrated skin screening and SDR-PEP administration
Number of subjects: 100

Group type: COMPARATOR
Intervention: Health centre-based intervention with integrated skin screening and SDR-PEP administration
Number of subjects: 100
Study: 32408862

Group type: EXPERIMENTAL
Intervention: C-MAC D-Blade videolaryngoscope
Number of subjects: 95

Group type: COMPARATOR
Intervention: McCoy laryngoscope
Number of subjects: 95
Study: 35398627

Group type: EXPERIMENTAL
Intervention: Light + Caffeine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Light
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 33085589

Group type: EXPERIMENTAL
Intervention: Sera with low ELISA optical density (OD) values (0.4-1)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Sera with intermediate ELISA OD values (>1-2.5)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Sera with high ELISA OD values (>2.5)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Sera with low 4T score
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Sera with intermediate 4T score
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Sera with high 4T score
Number of subjects: 38
Study: 36199771

Group type: EXPERIMENTAL
Intervention: Microwave ablation combined with anti-PD-1 monoclonal antibody
Number of subjects: 122

Group type: COMPARATOR
Intervention: Anti-PD-1 monoclonal antibody
Number of subjects: 122
Study: 33533898

Group type: EXPERIMENTAL
Intervention: R0 resection (n = 1196)
Number of subjects: 1399

Group type: COMPARATOR
Intervention: Final R1 resections (n = 131)
Number of subjects: 1399

Group type: COMPARATOR
Intervention: Margin conversion from IONM-positive to R0 resection (n = 72)
Number of subjects: 1399
Study: 35939520

Group type: EXPERIMENTAL
Intervention: Sanitation intervention (improved latrines, sani-scoops, children's potties, in-person behavioral promotion)
Number of subjects: 720

Group type: COMPARATOR
Intervention: Control arm (no sanitation intervention)
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Sanitation intervention
Number of subjects: 720

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 720
Study: 33607060

Group type: EXPERIMENTAL
Intervention: ACEi or ARB treatment (n=3601)
Number of subjects: 9365

Group type: COMPARATOR
Intervention: No ACEi or ARB treatment (n=3601)
Number of subjects: 9365
Study: 35655178

Group type: EXPERIMENTAL
Intervention: Workstation intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 60
Study: 32126990

Group type: EXPERIMENTAL
Intervention: ICMA (intracameral combination of 2 mydriatics and 1 anesthetic)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Topical regimen (conventional treatment)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: ICMA
Number of subjects: 57

Group type: COMPARATOR
Intervention: Topical regimen
Number of subjects: 57
Study: 35642684

Group type: EXPERIMENTAL
Intervention: Mozart's Sonata
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Instrumental music
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Silence
Number of subjects: 70
Study: 33216815

Group type: EXPERIMENTAL
Intervention: Free water elimination
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Free water content and mean diffusivity measured along the cingulum
Number of subjects: 68
Study: 34850368

Group type: EXPERIMENTAL
Intervention: Test formulation of sitagliptin phosphate/metformin hydrochloride tablets (50 mg/850 mg) under fasting conditions
Number of subjects: 48

Group type: COMPARATOR
Intervention: Reference formulation (JANUMET®) under fasting conditions
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Test formulation of sitagliptin phosphate/metformin hydrochloride tablets (50 mg/850 mg) under fed conditions
Number of subjects: 48

Group type: COMPARATOR
Intervention: Reference formulation (JANUMET®) under fed conditions
Number of subjects: 48
Study: 33096550

Group type: EXPERIMENTAL
Intervention: 5 oz-equivalent/d of protein foods
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 12.5 oz-equivalent/d of protein foods
Number of subjects: 51

Group type: COMPARATOR
Intervention: Both protein intake groups (5 oz and 12.5 oz)
Number of subjects: 51
Study: 35480507

Group type: EXPERIMENTAL
Intervention: Del Nido cardioplegia (DN)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saint Thomas cardioplegia (ST)
Number of subjects: 80
Study: 36055332

Group type: EXPERIMENTAL
Intervention: Pegcetacoplan (1080 mg subcutaneously twice weekly)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Eculizumab to pegcetacoplan
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Pegcetacoplan monotherapy
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Pegcetacoplan-to-pegcetacoplan
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Eculizumab-to-pegcetacoplan
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 80
Study: 34593587

Group type: EXPERIMENTAL
Intervention: SBCC intervention by community health workers (CHWs)
Number of subjects: 0
Study: 34856212

Group type: COMPARATOR
Intervention: CWC with AH Plus sealer
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: SBO with Endoseal TCS
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Both groups (CWC and SBO)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Teeth with sealer extrusion
Number of subjects: 74
Study: 33211326

Group type: EXPERIMENTAL
Intervention: Multicomponent lipid emulsion (MLE)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Soybean-based lipid emulsion (SLE)
Number of subjects: 128
Study: 36123153

Group type: EXPERIMENTAL
Intervention: Tanden breathing (video-guided, 10 min once a day for 6 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tanden breathing (intervention group)
Number of subjects: 20
Study: 35836830

Group type: EXPERIMENTAL
Intervention: RIF
Number of subjects: 19

Group type: COMPARATOR
Intervention: ATO
Number of subjects: 19
Study: 33434408

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 1 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 25 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 25 mg (Cohort B)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (Cohort A)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (Cohort B)
Number of subjects: 21
Study: 32114808

Group type: EXPERIMENTAL
Intervention: Arthroscopic subacromial decompression (ASD)
Number of subjects: 2217

Group type: EXPERIMENTAL
Intervention: Acromioclavicular joint excision (ACJE)
Number of subjects: 2217

Group type: EXPERIMENTAL
Intervention: Rotator cuff repair (RCR)
Number of subjects: 2217
Study: 34762378

Group type: EXPERIMENTAL
Intervention: Acupuncture for regulating spleen and stomach combined with aspirin enteric‐coated tablets
Number of subjects: 68

Group type: COMPARATOR
Intervention: Aspirin enteric‐coated tablets (100 mg once daily)
Number of subjects: 68
Study: 32513836

Group type: EXPERIMENTAL
Intervention: pTVG-AR vaccine with or without GM-CSF adjuvant
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: pTVG-AR vaccine
Number of subjects: 40
Study: 35616018

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (ET)
Number of subjects: 2130
Study: 34725379

Group type: EXPERIMENTAL
Intervention: High current density tACS (1 mA; 10 Hz and 20 Hz; 0.32 mA/cm2) for 20 min over bilateral sensorimotor areas
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham tACS
Number of subjects: 30
Study: 35867853

Group type: COMPARATOR
Intervention: Oral tianeptine (50 mg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Intravenous tianeptine (500 to 2000 ng/ml)
Number of subjects: 23
Study: 34843346

Group type: EXPERIMENTAL
Intervention: Prolonged exposure (PE) therapy, delivered in a massed format (daily sessions across 2 weeks)
Number of subjects: 0
Study: 32763196

Group type: EXPERIMENTAL
Intervention: NIS4 blood-based diagnostic test
Number of subjects: 702
Study: 36306151

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Hypocaloric diet
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: All treatments (Liraglutide, Diet, Sitagliptin)
Number of subjects: 88
Study: 34402199

Group type: EXPERIMENTAL
Intervention: Problem-solving therapy intervention
Number of subjects: 842

Group type: COMPARATOR
Intervention: Control arm (not specified)
Number of subjects: 842
Study: 32219359

Group type: EXPERIMENTAL
Intervention: Apabetalone (100 mg orally twice daily)
Number of subjects: 2425

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2425
Study: 35421017

Group type: EXPERIMENTAL
Intervention: d-mannose
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 71
Study: 33847018

Group type: EXPERIMENTAL
Intervention: L‐PRF
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: A‐PRF+
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study: 36177972

Group type: EXPERIMENTAL
Intervention: Forehead cooling (pre-frontal cortex cooling)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 34
Study: 34769849

Group type: EXPERIMENTAL
Intervention: Athletics Injury Prevention Programme (AIPP) 2/week
Number of subjects: 840

Group type: COMPARATOR
Intervention: Regular training (Control)
Number of subjects: 840
Study: 32165032

Group type: EXPERIMENTAL
Intervention: Home-based therapy (DVD)
Number of subjects: 44

Group type: COMPARATOR
Intervention: In-person therapist
Number of subjects: 44
Study: 36128663

Group type: EXPERIMENTAL
Intervention: Tocilizumab (8 mg/kg intravenously) every 4 weeks for 24 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo every 4 weeks for 24 weeks
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Tocilizumab (8 mg/kg intravenously)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 33389776

Group type: EXPERIMENTAL
Intervention: Mirabegron
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 32713072

Group type: EXPERIMENTAL
Intervention: Near-infrared radiation (NIR) application to skin
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (no NIR application)
Number of subjects: 11
Study: 32423329

Group type: EXPERIMENTAL
Intervention: Baseline HIR (Hypoperfusion Intensity Ratio)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Baseline CBV Index (Cerebral Blood Volume)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: 24-h HIR
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: 24-h CBV Index
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: 24-h CBV Index for smaller than predicted infarcts
Number of subjects: 123
Study: 36288924

Group type: EXPERIMENTAL
Intervention: CCTA-guided management
Number of subjects: 250

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 250
Study: 32735952

Group type: EXPERIMENTAL
Intervention: Acute hyperglycaemia (mean blood glucose: 321 ± 29 mg/dL)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Euglycaemia (mean blood glucose: 138 ± 34 mg/dL)
Number of subjects: 18
Study: 33220353

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 32583994

Group type: EXPERIMENTAL
Intervention: 800 micrograms misoprostol per rectally half an hour before surgery
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 50
Study: 34887241

Group type: EXPERIMENTAL
Intervention: 3T MRI
Number of subjects: 100

Group type: COMPARATOR
Intervention: 1.5T MRI
Number of subjects: 100
Study: 33449070

Group type: EXPERIMENTAL
Intervention: High-quality research (Level I) from randomized, controlled trials
Number of subjects: 2920

Group type: EXPERIMENTAL
Intervention: Moderate quality research (Level II) from observational studies
Number of subjects: 2920

Group type: EXPERIMENTAL
Intervention: Low quality research (Level III) from expert opinion
Number of subjects: 2920

Group type: COMPARATOR
Intervention: Original guidelines vs. updated guidelines for Clostridium difficile
Number of subjects: 2920

Group type: COMPARATOR
Intervention: Original guidelines vs. updated guidelines for candidiasis
Number of subjects: 2920

Group type: COMPARATOR
Intervention: Original guidelines vs. updated guidelines for coccidiomycosis
Number of subjects: 2920
Study: 34642832

Group type: EXPERIMENTAL
Intervention: Recovery Assessment Scale (RAS)
Number of subjects: 56
Study: 33428583

Group type: EXPERIMENTAL
Intervention: Durvalumab (D) 1500 mg/tremelimumab (T) 75 mg (intravenously every 4 weeks without SBRT)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Immune-sensitizing SBRT to one selected tumor site (9 Gy × 3 fractions) followed by D/T
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Pooled efficacy of D/T±SBRT in 15 RECIST evaluable patients
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Adverse events in arm A
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Adverse events in arm B
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Changes in peripheral blood lymphocyte and TILs
Number of subjects: 18
Study: 35989575

Group type: EXPERIMENTAL
Intervention: Anger self‐management training (ASMT)
Number of subjects: 54